| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_025e7fc746abe7ef4b2a6a9b3ae59de1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff3af9be8a609c3353a16b684caaae1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1ca2fe5a1e9022aa0323cbb48d30f5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49631cd1b9f8b3b50969244442e3a1d1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2000-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad7fb154afebb701173f447d5a86d869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b21052a8ccc960306bc94ac07469a901
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3385e1d8980ffc4d6ab6aa477167536 |
| publicationDate |
2001-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0125450-A1 |
| titleOfInvention |
Use of soluble costimulatory factor for tumor immuno-gene therapy |
| abstract |
A new gene therapy entails tumor treatment by introducing an expressible nucleotide sequence for a soluble costimulatory factor, thereby enhancing the response of T-cells to a tumor. In vivo expression of the soluble factor overcomes anergy or tolerance to tumor cells and activates T-cells that are infiltrating or surrounding the tumor. A pharmaceutical composition containing such a gene is effective in tumor suppression. |
| priorityDate |
1999-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |